RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

    Not Recruiting
  • End date
    Mar 8, 2023
  • participants needed
  • sponsor
    CymaBay Therapeutics, Inc.
Updated on 14 September 2022
Barry Crittenden, MD
Primary Contact
University Health Network (7.6 mi away) Contact
+157 other location


To evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo

Condition Primary Biliary Cholangitis
Treatment Placebo, seladelpar 10 mg, Seladelpar 5 mg
Clinical Study IdentifierNCT04620733
SponsorCymaBay Therapeutics, Inc.
Last Modified on14 September 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note